Please assess the completion status of the following clinical trial:

Trial Title: Gap Junction Potentiation of Endothelial Function With Rotigaptide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers aged between 18-64 years.~Exclusion Criteria:~* Lack of informed consent~* Age \<18 or \>64 years~* Current involvement in a clinical trial~* Clinically significant comorbidity: heart failure, hypertension, known hyperlipidaemia, diabetes mellitus, asthma, coagulopathy or bleeding disorders\*~* Smoker\*~* Current intake of aspirin, other non steroid anti inflammatory medications or vasodilators\*~* Recent infective/inflammatory condition\*~* Women of child bearing age~* Recent blood donation (preceding three months) \*All cause confounding effects on vascular/endothelial function.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Rotigaptide (Type: ACTIVE_COMPARATOR): Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
- Saline (Type: PLACEBO_COMPARATOR): Saline will be infused through-out the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).